| Autor: |
Psaros Einberg A; a Department of Clinical Science, Intervention and Technology (CLINTEC) , Karolinska Institutet , Stockholm , Sweden.; b Department of Pediatrics , Karolinska University Hospital , Stockholm , Sweden., Ekman AT; a Department of Clinical Science, Intervention and Technology (CLINTEC) , Karolinska Institutet , Stockholm , Sweden., Söderhäll S; b Department of Pediatrics , Karolinska University Hospital , Stockholm , Sweden.; c Department of Women's and Children's Health (KBH) , Karolinska Institutet , Stockholm , Sweden., Millbourn C; d Department of Medicine , Huddinge Karolinska Institutet , Stockholm , Sweden.; e Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden., Lindahl K; d Department of Medicine , Huddinge Karolinska Institutet , Stockholm , Sweden.; e Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden., Harila-Saari A; f Department of Women's and Children's Health , Uppsala University , Uppsala , Sweden., Fischler B; a Department of Clinical Science, Intervention and Technology (CLINTEC) , Karolinska Institutet , Stockholm , Sweden.; b Department of Pediatrics , Karolinska University Hospital , Stockholm , Sweden. |
| Abstrakt: |
Background: Childhood cancer survivors treated before 1992, when blood donor screening for hepatitis C virus (HCV) infection was introduced, are at risk of transfusion-transmitted HCV infection. A national HCV screening campaign targeting blood transfusion recipients was launched in Sweden in 2007-2010. The aims of this study were to, among adult childhood cancer survivors in Stockholm County, investigate the prevalence of HCV infection, the natural course of infection, treatment outcome and anti-HCV testing frequency before, during and after the screening campaign and finally to actively screen the untested ones. Material and Methods: This was a combined retrospective register based and prospective screening study of adult childhood cancer survivors ( n = 686) treated for malignancy in Stockholm before 1992. In the first part, we investigated the prevalence of HCV infection and previous anti-HCV testing, and in the second part, we actively traced and HCV-screened the remaining untested cohort living in Stockholm. Analysis of previous documented anti-HCV tests in medical records, laboratory records, and the national communicable disease registry was performed. In the second part, 231 presumably untested individuals were contacted by mail and offered an anti-HCV test. The natural course of HCV infection and treatment outcome was analyzed for those found to be chronically infected. Results: In total, 235 patients were tested and 11 were HCV-RNA positive. The overall prevalence of chronic HCV infection among the tested childhood cancer survivors was thus 4.7% (95% CI = 2.6-8.2%), which is almost 10 times higher than the national prevalence of 0.5%. Only 12% of the Stockholm cohort were tested during the screening campaign in 2007-2010, while the test uptake using active tracing screening within this study was 40% ( p < .001). Conclusion: With today's effective treatment options, active tracing and HCV screening of childhood cancer survivors are recommended. |
